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Gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter of the mam-
malian brain, can induce coma. Outside thecentral nervous system it is synthesized by gut bac-
teria and catabolized largely in the liver. GABA and its agonists, as well as benzodiazepines
and barbiturates, induce neural inhibition as a consequence of their interaction with specific
bindingsites for each ofthese classes ofneuroactive substances on the GABAreceptor complex
ofpostsynaptic neurons. In a rabbit model of acute liver failure: (i) the pattern ofpostsynaptic
neuronal activity in hepatic coma, as assessed by visual evoked potentials, is identical to that
associated with coma induced by drugs which activate the GABA neurotransmitter system
(benzodiazepines, barbiturates, and GABA agonists); (ii) the levels of GABA-like activity in
peripheral blood plasma increase appreciably before the onset ofhepatic encephalopathy, due
at least in part to impaired hepatic extraction ofgut-derived GABA from portal venous blood;
(iii) the blood-brain barrier becomes abnormally permeable to an isomer ofGABA, a-amino-
isobutyric acid, before the onset ofhepaticencephalopathy; and(iv) hepatic coma is associated
with an increase in thedensity ofreceptors for GABA and benzodiazepines in the brain. These
findings are the bases of the following hypotheses: (i) when the liver fails, gut-derived GABA
in plasma crosses anabnormally permeable blood-brain barrier andbymediating neuralinhibi-
tion contributes to hepatic encephalopathy; (ii) an increased number ofGABA receptors in the
brain found in liver failure increases the sensitivity of the brain to GABA-ergic neural inhibi-
tion; and (iii) an increased number of drug binding sites mediates the increased sensitivity to
benzodiazepines and barbiturates observed in liver failure by permitting increased drug effect.
INTRODUCTION
Hepatocellular failure, whether acute or chronic, is characterized by jaundice,
fluid retention, a hemorrhagic diathesis, and hepatic encephalopathy [1]. Of these
four complications of liver disease the pathogenesis of hepatic encephalopathy is
least well understood. It has not even been established whether hepatic encephalop-
athy occurs as a result of failure of the liver to synthesize a substance that is neces-
sary for the maintenance of normal brain function or failure ofthe liver to metabo-
lize adequately neuroactive substances that are capable ofinducing encephalopathy.
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All rights of reproduction in any form reserved.However, two observations tend to favor the second of these possibilities. The first
is the clinical finding that the administration of therapies which reduce the produc-
tion of nitrogenous substances by gut bacteria is often followed by an amelioration
ofhepatic encephalopathy inpatients with cirrhosis [1,2]. The second is the result of
carefully conducted cross-circulation experiments between normal and liverless rats
in which the electroencephalogram of the liverless rats was monitored. Brain func-
tion of liverless rats was found to improve more rapidly when their aortic blood was
infused into the portal vein (systemic-portal cross-circulation) rather than the jugu-
lar vein (systemic-systemic cross-circulation) of normal rats [3].
As aconsequence of theimpaired hepatic metabolism of many substances in liver
failure a large number of metabolites accumulate in plasma. Some of these metabo-
lites are neuroactive [2,4-8]. However, it is not apparent which, ifany, of the neuro-
active metabolites that accumulate in liver failure plays a central role in the patho-
genesis ofhepatic encephalopathy. Clearly if a metabolite in plasma contributes to
the mediation ofhepatic encephalopathy it must gain access to the brain by crossing
the blood-brain barrier. Many studies, in which attempts have been made to draw
inferences concerning the pathogenesis of hepatic encephalopathy, have involved
deriving correlations between levels ofputatively neuroactive metabolites in plasma,
cerebrospinal fluid, or brain, and the degree of severity of hepatic encephalopathy
[2,4-8]. When such a correlation is found there are three possible explanations:
(i) the increased level ofthe metabolite is causally related to hepatic encephalopathy;
(ii) the increased level ofthe metabolite occurs as a consequence of hepatic encepha-
lopathy; and(iii) some other pathophysiologic disturbance, perhaps liver failure
perse, causes bothhepatic encephalopathy and the increased level of the metabolite.
Furthermore, it isimportant toemphasize that because ofthe regional and subcellu-
lar compartmentalization of substances within the brain [9] mean changes in the
concentration ofa metabolite in the brain may not be relevant to the pathogenesis of
hepaticencephalopathy. However, changes in the concentration of a metabolite at a
critical site within the brain, such as synaptic clefts, could well be of critical impor-
tance [10]. A major deficiency of most hypotheses of the pathogenesis of hepatic
encephalopathy is that the presence of putative neurotoxins cannot be correlated
with specific neural mechanisms [7,8]. It seems unlikely that major advances in
elucidating the pathogenesis ofhepatic encephalopathy will come from studies that
rely solely on measuring the levels of metabolites. Important clues as to which com-
pounds areimportant in thepathogenesis ofhepatic encephalopathy may, however,
come from studies designed to throw light on which neurophysiologic mechanisms
could conceivably mediate the syndrome [10].
Four hypotheses of the pathogenesis of hepatic encephalopathy have received
most attention. These are that the syndrome is mediated by (i) ammonia-induced
neurotoxicity [2,7,8,11]; (ii) synergistic neurotoxic interactions between ammonia,
mercaptans, and fatty acids [7,8]; (iii) false neurotransmitter-induced neural inhibi-
tion [12-14]; and (iv) activation of the gamma-aminobutyric acid (GABA) inhibi-
tory neurotransmitter system [10,15]. Some of the observations on which the first
three ofthese hypotheses are based and some ofthe main deficiencies of these three
hypotheses have recently been discussed elsewhere [16,17]. This review article con-
centrates on the last and most recent of the four hypotheses, the GABA hypothesis.
After briefly reviewing some important aspects of GABA metabolism and stating
the GABAhypothesis, theinterpretation and potential significance of experimental
findings whichhave been cited insupport oftheGABAhypothesis are discussed. To
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conclude, some current perspectives and speculations relating to the GABA hypoth-
esis and other hypotheses of the pathogenesis of hepatic encephalopathy are given.
GABA METABOLISM
GABA is the principal inhibitory neurotransmitter of the mammalian brain. It is
synthesized in presynaptic neurons by decarboxylation of glutamate (Fig. 1). The
total brain content of GABA is 200-1,000 times greater than that of the biogenic
amine neurotransmitters. GABA is stored in cytoplasmic vesicles within presynaptic
neurons. Presumably GABA at these intracellular sites exerts no biological effect.
When released from presynaptic storage sites it enters the synaptic cleft and binds to
receptors on postsynaptic neurons. The interaction between GABA and its receptors
results in increased chloride ion conductance across the postsynaptic neural mem-
brane, hyperpolarization, and the generation of an inhibitory postsynaptic poten-
tial. GABA is quickly eliminated from the synaptic cleft by efficient mechanisms of
re-uptake into astrocytes and neurons and is either reincorporated into storage vesi-
cles or catabolized. GABA transaminase is the enzyme which mediates the biotrans-
formation of GABA to succinic semialdehyde, which is a precursor of succinic acid
[18-20] (Fig. 1).
The GABA receptor on postsynaptic neurons consists of a supramolecular com-
plex which possesses sites on its external surface for the interactive but noncompeti-
tive binding of at least three classes of synergistic ligands -GABA and its agonists,
benzodiazepines, and barbiturates. The sedative-hypnotic effects of benzodiazepines
and barbiturates are mediated by the GABA neurotransmitter system. The binding
of a benzodiazepine or a barbiturate to its binding site on the GABA receptor com-
plex potentiates the response to GABA by augmenting GABA-induced chloride ion
conductance across the membrane [21-24]. Benzodiazepines increase the frequency
of chloride channel opening whereas barbiturates increase the average time that
chloride channels are open [25].
THE GABA HYPOTHESIS
The GABA hypothesis relating to the pathogenesis of hepatic encephalopathy
consists of three components: (i) when the liver fails, gut-derived GABA in plasma
crosses an abnormally permeable blood-brain barrier and by mediating neural inhi-
bition contributes to hepatic encephalopathy; (ii) an increased number of GABA re-
ceptors in the brain found in liver failure increases the sensitivity of the brain to
GABA-ergic neural inhibition; and (iii) an increased number of drug binding sites
mediates the increased sensitivity to benzodiazepines and barbiturates observed in
liver failure by permitting increased drug effect [10,15].
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FIG. 1. The synthesis and catabolism of y-aminobutyric acid (GABA).
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AS SUPPORTING THE GABA HYPOTHESIS
Data Obtained Using Animal Models ofHepatic Encephalopathy
Most ofthe experimental findings that are cited in support ofthe GABA hypothe-
sis have been generated using a rabbit model of galactosamine-induced fulminant
hepatic failure [26]. This model has been well characterized. Galactosamine is a se-
lective hepatotoxin. It induces acute liver failure, followed by hepatic encephalopa-
thy, hepatic coma, and death. The model fulfills the requirements of an appropriate
animal model ofhepatic encephalopathy [27] in that the encephalopathy is reversible
(e.g., by cross-circulation with a normal rabbit [Schafer DF: unpublished observa-
tions]), the model is reproducible, death is from liver failure, the animal is sufficiently
large for most experimental purposes, and the model is not hazardous to laboratory
personnel. This model is regarded as one of the most satisfactory animal models of
acute hepatic encephalopathy [28]. The issue arises overwhether findings supporting
the GABA hypothesis using this model are specific for this model or would also be
found in other models of acute and chronic hepatic encephalopathy. Indeed, another
pertinent issue is whether findings supporting the GABA hypothesis are specific for
the syndrome of hepatic encephalopathy or also apply to other metabolic encepha-
lopathies.
The Effect of GABA on Consciousness
A crucial property of a substance ofimportance in the pathogenesis ofhepatic en-
cephalopathy would be that it can induceencephalopathyand coma. GABA appears
to fulfill this requirement. It is not only a potent inhibitor of single neurons [29],
but, in a potentially important study conducted by Smialowski [30], it was shown
that GABA can probably induce coma as well. Within ten seconds ofthe instillation
of less than 1 itmole of GABA into the hippocampal region ofconscious rabbits the
animals "became quiet; the spontaneous locomotoractivity declined and theanimals
mostlylay on the cage floor." These behavioral changes were associated with the de-
velopment of spreading delta-wave electroencephalographic activity similar to that
reported in man [31] and rabbits [26] with hepatic encephalopathy. Furthermore,
when large doses of GABA were administered intravenously to normal rabbits coma
was induced [Ferenci P, Pappas SC: unpublished observations]. This observation
presumably indicates that when the plasma content of GABA is increased to suffi-
ciently high levels, the absolute quantities of GABA that traverse an intact blood-
brain barrier in this nonphysiologic situation are large enough to induce a degree of
activation of the GABA neurotransmitter system that is sufficient to result in clin-
ically overt encephalopathy. The issue whether in liver failure GABA itself in the
quantities available for distribution to synaptic clefts could mediate encephalopathy
is crucial to the feasibility of the GABA hypothesis. Accordingly, further studies of
the ability of this inhibitory neurotransmitter to induce changes in mental status
would be of considerable interest and potential importance.
GABA-ergic Neurotransmission in Liver Failure
If activation of GABA-ergic neural mechanisms plays an important role in the
mediation of hepatic encephalopathy, then it would be expected that the pattern of
neuronal activity in the brain in this syndrome would be similar to that associated with
direct drug-induced activation of the GABA neurotransmitter system. The methods
currently available for studying changes in the patterns of neuronal activity associ-
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ated with different types ofencephalopathy are limited. Recordings ofthe electroen-
cephalogram seem to be too nonspecific and too difficult to quantitate to be useful
in this context [32]. However, the recording of visual evoked potentials (VEPs) ap-
pears to be more promising [33]. Indeed, measurements of VEPs in experimental
animals have been shown to be a useful objective measurement ofneuronal events in
encephalopathies, and it has been suggested that this technique may prove to be par-
ticularly useful in assessing the role ofaltered neurotransmission in the pathogenesis
of experimental hepatic encephalopathy [34,35].
When visual afferent stimuli are applied in the form of flashes of light, the central
nervous system responds by generating synchronous volleys of discharges through
neuronal networks [36,37]. This response constitutes the VEP. It can be monitored
via chronically implanted epidural electrodes. In practice, a computer of average
transients is used to derive the VEP from the electroencephalogram by averaging re-
sponses which are time-locked to the flashes of light and simultaneously removing
other noncoherent electroencephalographic activity [35].
The results of studies ofVEPs in an animal model of fulminant hepatic failure are
entirely consistent with hepatic encephalopathy being associated with activation of
GABA-ergic neural mechanisms [35,38]. The pattern of the VEP trace in the animal
model exhibited highly distinctive and reproducible abnormalities (Fig. 2) which are
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FIG. 2. The highly reproducible sequence of changes in the visual evoked poten-
tial waveform as a rabbit succumbs to galactosamine-induced fulminant hepatic
failure. Visual evoked potentials associated with four different clinical stages of
hepatic encephalopathy are depicted. The arrows indicate the time of the light flash
stimuli. The waveform in stage IV hepatic encephalopathy (hepatic coma) is iden-
tical to that found in coma induced by a benzodiazepine (diazepam), a barbiturate
(pentobarbital), or a GABA agonist (muscimol). (Reproduced from [35] with per-
mission of Gastroenterology).
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failure per se, but by direct drug-induced activation of the GABA neurotransmitter
system. The particular drugs used in these studies were the benzodiazepine, diazepam;
the barbiturate, pentobarbital; and the potent GABA agonist, muscimol [35]. In
contrast, the patterns of the VEP trace in animals with coma or encephalopathy in-
duced by a variety of neurotoxic agents (ether, ammonia, dimethyldisulfide, octa-
noic acid, a mixture of phenylalanine and tryptophan, and a mixture of subcoma
doses of ammonia, dimethyldisulfide, and octanoic acid), which do not act prefer-
entially on the GABA system, also exhibited highly distinctive and reproducible ab-
normalities, but these abnormal patterns were fundamentally different from the pat-
tern of the VEP trace in hepatic coma [35,38-40].
There are potential problems with the interpretation of studies of VEPs. There is
still debate regarding the precise origin of the VEP trace and correspondingly what
inferences can justifiably be drawn from changes in the pattern of VEPs [41]. VEPs
are summated measurements ofthe electrical activity in nervous tissue in response to
a stimulus. They probably "reflect excitatory postsynaptic potentials, inhibitory
postsynaptic potentials or some mixture of both" [37]. However, the observation
that VEP waveforms in different neurologic states are identical does not constitute
unequivocal proof that the different syndromes share common neural mechanisms.
Phenomena related to the generation and measurement of VEPs may influence the
results of VEP studies [42]. Nevertheless, the overall patterns of VEPs may be help-
ful in determining whether similar or dissimilar postsynaptic neural events are asso-
ciated with particular neurologic states. Thus, from the findings in the VEP studies
it would be reasonable to assume that the neurologic mechanisms which mediate
hepatic encephalopathy more closely resemble the neurologic mechanisms which
mediate drug-induced activation of the GABA neurotransmitter system [35], than
those associated with encephalopathies induced by a variety of other agents whose
effects on the central nervous system do not primarily involve activation of the
GABA neurotransmitter system [35,38-40].
The observation that the abnormal pattern of the VEP in experimental animals
with post-ictal coma is identical to that of animals in hepatic encephalopathy due to
fulminant hepatic failure [38], adds further support to the notion that hepatic en-
cephalopathy is associated with activation of the GABA neurotransmitter system,
since it has recently been found that activation of the GABA neurotransmitter sys-
tem appears to play a major role in the pathogenesis of post-ictal coma [43]. The
potential validity of inferences regarding which neural mechanisms mediate specific
neurologic syndromes from VEP data should become clearer when adequate data
correlating changes in VEPs with changes in cerebral physiology are available [41].
A GABA Agonist in Plasma in Liver Failure
At least three decades ago it became apparent that neuroactive nitrogenous prod-
ucts of gut bacteria were likely to play an important role in the pathogenesis of
hepatic encephalopathy. It was assumed that such substances are absorbed and are
normally extracted from portal venous blood and metabolized by the liver. It was
further assumed that in liver failure appreciable amounts of these substances gain
access to the systemic circulation and ultimately the brain as a result of passage
through portal-systemic venous collateral channels and/or impaired hepatic extrac-
tion [44]. As an alternative to hepatic encephalopathy, the term portal-systemic en-
cephalopathy was introduced to embrace these concepts, and this term has withstood
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the test oftime. When considering the GABA hypothesis in relation to portal-systemic
encephalopathy, it is germane to consider whether in liver failure a substance is pres-
ent in plasma which can bind to GABA receptors and whether intestinal bacteria are
a major source of such a substance.
The sensitive radioreceptor assay for GABA developed by Enna and Snyder [45]
depends on the principle that when 3H-GABA is incubated with synapticmembranes
the amount of 3H-GABA that specifically binds to the membranes is inversely pro-
portional to the total amount ofunlabeled GABA in the incubation medium. In other
words, this assay measures the concentration of GABA and/or other substances
which can bind to GABA receptors. Application of this assay has revealed that the
concentration of GABA-like activity in portal venous plasma is about twice that in
aortic plasma in normal rabbits [46], an observation which points to the gut as a
source of GABA. Furthermore, E. coli and B. fragilis isolated from human feces,
when cultured anaerobically, produce abundant quantities of GABA-like activity
[46]. These findings are consistent with the enteric bacterial flora being a source of
an appreciable amount ofthe GABA found in peripheral blood. Further application
of the radioreceptor assay has shown that peripheral blood plasma levels ofGABA-
like activity increase by an order of magnitude in an animal model of acute liver
failure before the onset of clinically overt hepatic encephalopathy [47]. In addition,
plasma levels ofGABA-like activitytend to beincreased several-fold in patients with
decompensated acute and chronic hepatocellular disease, particularly if hepatic en-
cephalopathy has developed [48]. Plasma levels of GABA-like activity do not in-
crease in rabbits in uremic coma [49], indicating that the increase in plasma levels of
GABA-like activity associated with hepatic encephalopathy is not a nonspecific
finding common to metabolic encephalopathies in general. The correlation between
plasma levels of GABA-like activity and the stage of hepatic encephalopathy in pa-
tients is not close [48]. However, this negative finding does not necessarily detract
from the GABA hypothesis since data on the prevailing permeability of the blood-
brain barrier in the patients studied are not available. Plasma levels of GABA-like
activity have been shown to increase several-fold in cirrhotic patients following hem-
orrhages into thegastrointestinal tract(Fig. 3) [48], an observation that suggests that
blood in the gut acts as a substrate for GABA synthesis by intestinal bacteria.
The specificity of the radioreceptor assay for GABA is not absolute. However, it
should be emphasized that very few physiologically occurring substances are known
to interfere with this radioreceptor assay. Two that have been cited are homocarno-
sine and j3-alanine, substances with affinities for GABA receptors that are, respec-
tively, 50 and 200 times less than that of GABA itself [45,48]. Furthermore, in rab-
bits in acute liver failure there is complete concordance between the ion-exchange
chromatography profiles ofthe GABA-like activity in plasma and 3H-GABA [10,15].
Thus, it seems probable that the GABA-like activity produced by intestinal bacteria
and detected in plasma in increased amounts in liver failure is due to GABA itself.
However, this inference has not been proved by applying another more specific as-
say for GABA. Attempts to separate GABA from other amino acids that are present
in very high concentrations in plasma in liver failure using high-performance liquid
chromatography and gas chromatography/mass spectroscopy have been unsuccess-
ful [48]. The technical problems currentlypreventing the definitive resolution ofthis
issue will almost certainly be overcome in due course.
The liver probably plays an important role in extracting gut-derived GABA from
portal venous blood. In the rabbit more than 80 percent ofthe total body activity of
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FIG. 3. The effect ofgastrointestinal hemorrhages on serum levels of GABA-like activity in
two patients with cirrhosis. A = before bleeding; B = 12-16 hours after bleeding; t = died.
(Reproduced from [48J with permission of The Lancet).
GABA transaminase, the enzyme responsible for GABA catabolism, has been found
to be present in the liver [50]. Accordingly, reduced hepatic catabolism ofgut-derived
GABA may contribute to the elevated plasma levels of GABA-like activity found in
liver failure. Both nonmodel-dependent [47] and model-dependent [51] analyses of
data on the in vivo kinetics and catabolism of 3H-GABA in rabbits have confirmed
that hepatic extraction of GABA is reduced in acute liver failure. However, both
analyses also indicated that the magnitude of the decrease in hepatic clearance was
not sufficient to account for the magnitude ofthe increase in plasma GABA-like ac-
tivity observed in acute liver failure. Thus, studies of GABA metabolism in vivo not
only provide support for the notion that gut-derived GABA contributes to the in-
creased plasma levels of GABA-like activity in liver failure, but they also suggest that
in liver failure there is an increase in the delivery rate of GABA into the circulation.
The mechanism of the latter phenomenon is unknown; possibilities include increased
absorption ofGABA from the gut and increased brain-to-plasma transfer ofGABA
across the blood-brain barrier.
Thus, from the available experimental findings it can be concluded that in liver
failure there is an increased ability ofplasma to displace 3H-GABA from GABA re-
ceptors on postsynaptic membranes and that a major source of this plasma GABA-
like activity is the enteric bacterial flora. It is assumed, but it has not been proved,
that the GABA-like material in plasma in liver failure is not a GABA antagonist but
a GABA agonist.
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Permeability ofthe Blood-Brain Barrier to GABA in Liver Failure
Clearly if gut-derived GABA contributes to the neural inhibition of hepatic en-
cephalopathy, it is necessary for GABA in plasma to gain access to the brain by
crossing the blood-brain barrier. This barrier consists of a continuous layer of capil-
lary endothelial cells which are almost devoid of vesicles and are joined together by
tight intercellular junctions (Fig. 4). Normally the transcapillary movement of most
solutes and water is greatly hindered by this barrier [52]. GABA moves across the
normal intact blood-brain barrier slowly by what appears to be anonspecific process
[53]. A potential problem with trying to quantitate the blood-to-brain transfer of
GABA directly is the rapid metabolism of GABA both within and outside the cen-
tral nervous system [18-20,24,47]. An isomer of GABA, a-aminoisobutyric acid
(AIB) [(CH3)2.C.NH2.COOH] is free from this disadvantage. 14C-labeled AIB has
several properties which make it a most attractive tracer to study the permeability of
the blood-brain barrier [54]: (i) it is not metabolized in mammals so that the distri-
bution ofthe label is not complicated by metabolism; (ii) it crosses the intact blood-
brain barrier relatively slowly; (iii) it is rapidly taken up by and trapped in brain cells
at the point where it crosses the blood-brain barrier, thereby minimizing backflow
of label across the blood-brain barrier and diffusive and convective flow of label
through the extracellular space of the brain; (iv) it is rapidly cleared from plasma;
and (v) its transfer across the blood-brain barrier is not mediated by aspecific amino
acid carrier system but is a function of its lipid solubility and diffusivity. Because of
the last of these properties an increase in the transfer of AIB across the blood-brain
barrier implies a nonspecific increase in the permeability ofthe blood-brain barrier.
The transfer of 14C-AIB across the blood-brain barrier has been studied in rabbits
in acute liver failure. The methods used involved computerized imaging techniques
combined with quantitative autoradiography of sections of the brain to produce
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309color-referenced representations of the blood-to-brain transfer of 14C-AIB. In nor-
mal rabbits transfer of 14C-AIB across the barrier was minimal. However, with the
onset of acute liver failure there was an increase in the permeability of the blood-
brain barrier to 14C-AIB in certain gray matter areas of the brain. This change in
permeability occurred several hours before the onset of clinically overt hepatic en-
cephalopathy [54]. This finding implies a nonspecific increase in the permeability of
the blood-brain barrier in acute liver failure. This inference is also supported by the
finding that hepatectomy in rats is followed by an increase in the permeability of the
blood-brain barrier to L-glucose, D-sucrose, inulin, and trypan blue dye [55]. Such a
nonspecific increase in the permeability of the blood-brain barrier would presum-
ably facilitate increased transfer of GABA from plasma to the extracellular fluid of
the brain in liver failure before the onset of hepatic encephalopathy.
The mechanism of the increased permeability of the blood-brain barrier in acute
liver failure could be an increase in transcapillary vesicular transport, as suggested
by the ultrastructural observation of a marked increase in the number of vesicles
within cerebral capillaries of rats with surgically created portacaval shunts [56]. Al-
ternatively, the mechanism could be the opening of a few intercellular tight junc-
tions of cerebral capillaries, a phenomenon which may be difficult to demonstrate
ultrastructurally.
The Status of the GABA Neurotransmitter System in Liver Failure
If enhanced GABA-ergic neurotransmission plays an important role in the media-
tion of hepatic encephalopathy, changes in the GABA neurotransmitter system in
the brain might be expected in liver failure. To assess the functional status of the
GABA neurotransmitter system in liver failure, measurements have been made of
the specific binding of3H-GABA and3H-flunitrazepam to postsynaptic neural
membranes prepared from the brains of rabbits. Scatchard plot analysis of the
GABA binding data suggested the presence of two independent classes of receptors
with different (high and low) affinities. The development of hepatic coma due to
acute hepatic failure was associated with no changes in the affinities but with an in-
crease of about twofold in the densities of both GABA receptors [57,58] (Fig. 5).
Scatchard plots of the benzodiazepine binding data indicated a single class of bind-
ing sites. The development of hepatic coma was associated with no change in the af-
finity but with an increase of about 40 percent in the number of these binding sites
[58,59] (Fig. 6). These findings suggest that binding sites for GABA and benzodiaze-
pines on the GABA receptor complex are regulated as a single operational unit. In
an analogous study in rats, in which there also appeared to be two classes of recep-
tors for GABA, mild hepatic encephalopathy was also associated with an increase in
the density of both classes of receptors, but more severe hepatic encephalopathy
was associated with a loss of high affinity receptors [60]. Similar changes in GABA
receptors to those found in this study in rats have also been found in mild and se-
vere hepatic encephalopathy in a dog model of chronic liver failure [61] and in pa-
tients who had died with cirrhosis and hepatic encephalopathy [62]. Not surprisingly
the human autopsy data are not as clear-cut as the animal data, but nevertheless
appear to show that the pattern of changes in GABA receptors associated with he-
patic encephalopathy does not occur in patients dying from a variety of nonhepatic
causes [62].
Changes in neurotransmitter receptors in hepatic encephalopathy are not limited
to the GABA neurotransmitter system. In rabbits with acute liver failure, hepatic
coma is associated with an increase in the density of receptors for another inhibitory
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amino acid neurotransmitter, glycine; a decrease in the density of receptors for three
excitatory amino acid neurotransmitters, glutamate (the principal excitatory
neurotransmitter of the mammalian brain), aspartate, and kainic acid; and no ap-
preciable change in the densities of receptors for certain nonamino acid neuro-
transmitters, specifically dopamine, opiates (A-opiate), enkephalins (6-opiate), and
acetylcholine (63,64]. The specificity of this pattern of changes in neurotransmitter
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311receptors for the syndrome of hepatic encephalopathy has not been established.
However, the observation in rabbits that uremic coma is not associated with any
appreciable changes in the densities of GABA [58] or glutamate [Ferenci P: unpub-
lished observations] receptors indicates that the changes in the densities of these
receptors found in hepatic encephalopathy are not common to metabolic encephalo-
pathies in general.
The mechanisms underlying the observed changes in neurotransmitter receptors in
hepatic encephalopathy are unknown. One possibility is that the changes are second-
ary to alterations in the composition of neural membranes. The cholesterol and
phospholipid content of synaptic membranes isolated from the cerebral cortex of
rabbits in hepatic coma due to acute liver failure has been found to be increased
without any associated changes in the relative composition of phospholipid sub-
classes or membrane protein content [65]. It is not clear whether such changes in the
composition of neural membranes reflect altered lipoprotein metabolism in neurons
or changes in the composition of lipoproteins in brain extracellular fluid. It is con-
ceivable that the increase in the lipid-to-protein ratio of synaptic membranes in
hepatic coma is associated with changes in the functions of membrane receptors.
The interpretation of the observed changes in neurotransmitter receptors in hepatic
encephalopathy is hindered by the paucity ofknowledge concerning the mechanisms
which normally regulate neurotransmitter receptors and whether these mechanisms
are operational in liver failure. The changes in GABA receptors in a rat model of
hepatic coma have been attributed to "denervation supersensitivity" [60]. As dener-
vation would be associated with a loss of presynaptic buttons which are rich in glu-
tamate decarboxylase, the observation that brain glutamate decarboxylase levels are
not reduced in an animal model ofhepatic coma provides no support for this possi-
bility [66].
The most important issue relating to the changes in neurotransmitter receptors in
liver failure is their behavioral implications. Unfortunately, it is not possible to ex-
trapolate from the available in vitro data on the binding of neurotransmitters to
their receptors in hepatic encephalopathy to in vivo events with any degree of con-
fidence. One possibility is that a neurotransmitter system becomes supersensitive to
its neurotransmitter when the concentration of that neurotransmitter in synaptic
clefts is decreased [67]. However, the most attractive potential implication of the
neurotransmitter binding data in hepatic encephalopathy, and one that is entirely
consistent with the GABA hypothesis, would be that the sensitivity of the brain to
neurotransmitters varies directly with their density [63,64]. Thus, it is possible that
in liver failure there is increased sensitivity to inhibitory amino acid neurotransmit-
ters, decreased sensitivity to excitatory amino acid neurotransmitters, and unaltered
sensitivity to other neurotransmitters which modulate neural function. Such changes
in the sensitivity ofthe brain to neurotransmitters afford a feasible pathophysiologic
basis for the neural inhibition which characterizes the syndrome of hepatic
encephalopathy. As GABA is the principal inhibitory neurotransmitter ofthe mam-
malian brain [18-20], an important component ofthis potential interpretation ofthe
neurotransmitter binding data in hepatic encephalopathy is the assumption that an
increase in the number of receptors for GABA in liver failure increases the sensitiv-
ity of the brain to GABA-ergic neural inhibition by permitting more interaction be-
tween GABA and its receptors [58]. Increased GABA-ergic neural inhibition in liver
failure could be mediated by GABA itself or by an as-yet-unidentified GABA
agonist.
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CONCLUDING PERSPECTIVES AND SPECULATIONS
As with other hypotheses of the pathogenesis of hepatic encephalopathy, the
GABAhypothesis hasnot beendefinitivelyvalidated. In contrastto otherhypotheses
such as the ammonia [2,7,8,11], the synergistic neurotoxins [7,8], and the false
neurotransmitter [12-14] hypotheses, in which the neural mechanisms responsible
for inducing encephalopathy have not been precisely defined, an attractive feature
of the GABA hypothesis is that the neural mechanisms responsible for mediating
neural inhibition when the GABA neurotransmitter system is stimulated are well
characterized [18-24,29]. Furthermore, some recent experimental data provide no
support for the ammonia, the synergistic neurotoxins, and the false.neurotransmit-
ter hypotheses. For example, it has not been possible to reproduce the abnormal pat-
tern of VEPs that is associated with an animal model of hepatic coma by infusing
ammonium chloride'or by administering simultaneously subcoma doses of am-
monium chloride, a mercaptan, and a fatty acid [38]. Also, it has not been possible
to reproduce the changes in receptors for'GABA and glutamate that occur in an
animal model of hepatic coma by infusing ammonium chloride [58,63,68]. Further-
more, while the false neurotransmitter hypothesis assumes that decreased dopa-
minergic .neurotransmission occurs in hepatic coma, the finding of no significant
changes in the molecular components of the postsynaptic dopamine receptor in an
animal model of hepatic coma [69], suggests that there is no appreciable change in
dopaminergic neurotransmission in hepatic coma. In one recent study the pattern of
VEPs in a rat model of hepatic coma was reported to be similar to that in rats with
coma induced by administering a mixture of subcoma doses ofammonia, a mercap-
tan, and a fatty acid [40]. However, in this study it is not completely clear whether
the animals in coma following the administration of the three neurotoxins had not
had an episode of seizures immediately preceding the onset of coma. Consequently
the possibility exists that the coma in these animals may not have been due to the
direct interactions of the three neurotoxins on the brain but rather to post-ictal
coma. Thus, the findings in this study are not necessarily incompatible with the
GABA hypothesis. Indeed, experimental data incompatible with this hypothesis
have yet to be generated.
Clearly further studies are necessary to determine definitively what role, if any,
the GABA neurotransmitter system plays in the pathogenesis of hepatic encepha-
lopathy. In particular, the applicability ofthis hypothesis to human hepatic enceph-
alopathy is currently unknown. Furthermore, it is not known whether the GABA
hypothesis applies to other metabolic encephalopathies. There is a need to study
GABA metabolism and the GABA neurotransmitter system in models of hepatic
coma other than galactosamine-induced fulminant hepatic failure, including models
of chronic liver failure. It would be highly desirable, using an appropriate model of
hepatic encephalopathy, to measure the concentration of GABA in synaptic clefts,
to assess the effects ofblocking GABA-ergic neurotransmission, and to make direct
measurements ofGABA-ergic neurotransmission. Such data should provide further
insights into the pathogenesis of hepatic encephalopathy.
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